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Abstract
Venous thromboembolism (VTE), deep vein thrombosis and pulmo-
nary embolism, are among the main causes of morbidity and mortality 
in pregnancy with an estimated incidence of 1 per thousand women 
years. Despite identification of maternal and pregnancy-specific risk 
factors for development of pregnancy-associated venous thromboe-
mbolism, limited data are available to inform on optimal approaches 
for prevention. The relatively low overall prevalence of pregnancy-
associated venous thromboembolism has prompted debate about 
the validity of recommendations, which are mainly based on expert 
opinion, and have resulted in an increased use of pharmacological 
thromboprophylaxis in pregnancy and postpartum. 
Keywords
Venous thromboembolism, pregnancy, thromboprophylaxis
Pulmonary embolism (PE) and deep venous thrombosis (DVT) are 
two components of a single pathophysiological process called ve-
nous thromboembolism (VTE). The PE usually occurs as a result of 
DVT, but often thrombosis is not diagnosed before the occurrence 
of embolia [1].
Thrombophilia are common disorders that increase the risk of preg-
nancy-associated venous thromboembolism and pregnancy loss and 
can also increase the risk of placenta-mediated pregnancy compli-
cations (severe pre-eclampsia, small-for-gestational-age infants, and 
placental abruption). Thrombophilia are common acquired or genetic 
predispositions to develop venous thromboembolism. Venous throm-
boembolism, which comprises deep vein thrombosis and pulmonary 
embolism, is more frequent in pregnant women than in non-pregnant 
age-matched women [2].
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Placenta-mediated pregnancy complications, 
comprising pre-eclampsia, birth of a small-for-ges-
tational-age infant, placental abruption, or preg-
nancy loss, are also common and lead to substan-
tial maternal and fetal or neonatal morbidity and 
mortality. Patients with previous placenta-mediated 
pregnancy complications have a raised risk of both 
recurrent placenta-mediated pregnancy complica-
tions and venous thromboembolism during subse-
quent pregnancies [2].
Thromboembolic events are among the leading 
causes of maternal morbidity and mortality in preg-
nancy and postpartum period. While the main cau-
se of maternal death in developing countries is blee-
ding, thromboembolic events are the leading cause 
of maternal death in developed countries, where 
death from bleeding is prevented. The incidence of 
these events varies between 0.76 to 1.72 per 1,000 
pregnancies, four to five times more often than wo-
men not pregnant [1].
Thrombotic risk factors have been associated 
with pregnancy complication. Many previous stu-
dies have found an association between inherited 
thrombophilia and adverse pregnancy outcomes, 
however there has been wide variability in the 
strength of the association and some studies have 
not found a relationship. Despite significant racial 
disparities in rates of adverse pregnancy outcomes, 
most studies examining the relationship of throm-
botic risk factors in women with adverse pregnan-
cy outcomes have been performed in white po-
pulations, and have focused on Factor V Leiden 
and prothrombin gene mutations, thrombotic risk 
factors known to be less prevalent among black 
populations [3]. 
The prevalence of diagnosed thrombophilia di-
ffered by race. Overall, thrombophilia was more 
common in white women with adverse pregnan-
cy outcomes compared to black women (44% vs 
30.3%, p = 0.04), although this difference was 
primarily due to the difference in factor V Leiden 
mutation (19% vs 3%, p b 0.01). However, pro-
tein S deficiency was significantly more common 
in black women (15.2% vs 5.8%, p = 0.02). When 
assessed among the subgroup of women who were 
not pregnant at study enrollment (252 white and 32 
black), protein S deficiency was still more common 
in black women but the difference did not reach 
statistical significance (13.5% vs 5.5%, p = 0.08). 
None of the women with protein S deficiency had 
sickle cell disease, renal disease, or HIV. Antithrom-
bin deficiency was also more common among black 
women (6% vs 1.5%, p = 0.04). There were no 
racial differences in the frequency of laboratory tes-
ting for protein S or antithrombin [3]. 
A meta-analysis showed that two-thirds of cases 
of DVT occurred during pregnancy and were equally 
distributed in the three quarters, while 43-60% of 
episodes of PE occurred in the postpartum period. 
DVT in the lower limb is the most common type of 
venous thromboembolism during pregnancy. Ap-
proximately 30% of the isolated cases are episodes 
of pulmonary embolism associated with DVT silent, 
and in patients presenting the symptoms of DVT 
and pulmonary embolism the frequency of PE is 
around 40-50%. The risk of venous thromboem-
bolism, added to pregnancy status, and even more 
if it is combined with other factors such as family 
or personal history of VTE, thrombophilia, age over 
35, obesity and high parity. Cesarean section also 
significantly increases the risk of thromboembolic 
events compared to vaginal delivery [1].
Thrombophilia, an entity that includes hereditary 
disorders and acquired associated with an increased 
tendency to develop VTE is a major determinant 
of this complication during pregnancy. The main 
hereditary conditions of thrombophilia include: an-
tithrombin deficiency of C and S proteins; mutations 
on prothrombin gene and factor V Leiden; homo-
zygous to methylenetetrahydrofolate reductase and 
hyperhomocysteinemia. As acquired thrombophilic 
states, we can mention the antiphospholipid syn-
drome (APS) and the nephrotic syndrome with con-
sequent decreased levels of antithrombin [1].
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A personal history of VTE is a significant risk 
factor for VTE during pregnancy. Women with a 
previous VTE have a 3 to 4 fold increased risk of 
recurrent events during subsequent pregnancies, 
with studies demonstrating rates of recurrence of 
6% to 8% during the antepartum and postpartum 
period, respectively. In a prospective study of 125 
pregnant women with a previous single episode of 
VTE, the incidence of antepartum and postpartum 
recurrence without prophylaxis was 2.4% (95% 
confidence interval [CI] 0.2%-6.9%) and 2.5% 
(95% CI 0.5%-7.0%), respectively. Evidence regar-
ding other prognostic factors for recurrent VTE has 
been conflicting. One post hoc analysis found a low 
risk of recurrence in women without thrombophilia 
with a temporary risk factor, including oral con-
traceptives or pregnancy-related VTE, at the time 
of their first event. Alternatively, retrospective stu-
dies have failed to show a consistent association 
between temporary risk factors and recurrent VTE. 
Investigators found women with a first VTE pro-
voked by use of oral contraceptives or related to 
pregnancy or the postpartum period were at a hig-
her risk of recurrent thromboembolism than those 
who experienced an episode of VTE provoked by 
a no hormonal transient risk factor; it should be 
noted however that this difference did not reach 
statistical significance. For women with a history 
of prior VTE, the American College of Chest Phy-
sicians classify risk as low, moderate, or high for 
recurrent VTE during pregnancy. Low-risk patients 
include those who have had a single episode of 
VTE associated with a transient risk factor, not in-
cluding pregnancy or use of estrogen; moderate to 
high-risk patients include those who experienced 
an idiopathic VTE, pregnancy or estrogen-related 
VTE, or multiple prior VTE not currently receiving 
anticoagulation [4].
Worldwide, numerous women achieve pregnan-
cy by the aid of in vitro fertilization (IVF). Until re-
cently, IVF treatment was regarded a risk factor for 
thrombosis based on reviews of case reports only. 
During IVF, controlled ovarian stimulation leads to 
multiple oocytes and supra-physiological levels of 
estrogens [5].
 The consequence is a pro-coagulant like state 
during pregnancy. Pregnancy per se increases the 
risk of venous thromboembolism (VTE), especially 
during the third trimester and the first 6 weeks af-
ter delivery. VTE, especially pulmonary embolism, 
remains a leading cause of maternal mortality [5].
Four studies have provided important evidence 
on the issue of whether IVF is a risk factor for VTE. 
Jacobsen et al. found that the VTE risk during preg-
nancy and the post-partum period was significantly 
increased compared with other pregnancies, and 
Henriksson et al. and Rova et al. showed a signi-
ficantly increased VTE risk among IVF-pregnancies 
during the first trimester. A group recently reported 
that there was no evidence of increased VTE risk 
after IVF treatment in unsuccessful cycles [5].
Current smokers had no apparent increased risk of 
venous thromboembolism relative to non-smokers, 
with a rate ratio of 0.9 (95% CI, 0.7 to 1.2). Women 
whose information on smoking was missing had a 
rate ratio of venous thromboembolism of 1.8 (95% 
CI 1.2-2.7) compared with non-smokers. Hypereme-
sis was associated with an increased risk of venous 
thromboembolism in pregnancy, with a rate ratio 
of 2.5 (95% CI, 1.4 to 4.5). Women with a BMI 
between 25 and 29.9 had a rate ratio of venous 
thromboembolism of 1.4 (95% CI, 1.0 to 2.0), rela-
tive to women with a BMI of 18.5 to 24.9, whereas 
values of BMI greater than 25 were not associated 
with notably increased risk for venous thromboem-
bolism. Multiple pregnancies were associated with a 
rate ratio for venous thromboembolism of 2.8 (95% 
CI, 1.9 to 4.2) compared with singleton pregnancies. 
Receiving antibiotic treatment for infection during 
pregnancy was associated with a rate ratio of ve-
nous thromboembolism of 1.8 (95% CI, 1.5 to 2.3). 
For women who had a discharge diagnosis of infec-
tion during pregnancy the rate ratio was 4.3 (95% 
CI, 2.7 to 7.1) adjusted for all confounders. Hospi-
InternatIonal archIves of MedIcIne
Section: Pulmonary and critical care medicine
Issn: 1755-7682 
2015
Vol. 8 No. 17
doi: 10.3823/1616
This article is available at: www.intarchmed.com and www.medbrary.com 4
talization 3-7 days during pregnancy increased the 
risk for venous thromboembolism 12.2 fold (95% 
CI, 8.7-17.0). Shorter and longer stays also increased 
the risk for venous thromboembolism, although less 
so. The risk associated with polyhydramnios was not 
assessed as there were few women with a diagno-
sis of polyhydramnios and only one case of venous 
thromboembolism among this women [6]. 
Smoking at the beginning of pregnancy was only 
weakly associated with risk of venous thromboe-
mbolism during the puerperal period. Treatment 
with antibiotics during pregnancy was associated 
with a rate ratio of venous thromboembolism in 
the puerperal period of 1.3 (95% CI, 1.0 to 1.6); 
the corresponding figure for women who were 
treated during the puerperal period was 1.4 (95% 
CI, 1.0 to 1.9). Women with a hospital diagnosis 
of infection in pregnancy or the puerperal period 
had a rate ratio of venous thromboembolism of 2.4 
(95% CI, 1.5 to 3.8) and 5.0 (95% CI, 2.4 to 10.6), 
respectively [6].
There was only a weak association between risk 
of venous thromboembolism and being hospitalized 
less than a week in the puerperal period, whereas 
women with a hospitalization of 8-14 days or more 
than 14 days had a rate ratio of 4.2 (95% CI, 3.0 
to 6.0) and 5.9 (95% CI, 4.0 to 8.8), respectively. 
Although there was a strong association between a 
multiple pregnancy and risk of venous thromboem-
bolism during pregnancy, the rate ratio in the puer-
peral period after carrying more than one fetus was 
only 1.3 (95% CI, 0.6 to 2.6) [6].
Compared with women of normal BMI, women 
with BMI between 25 and 29.9, 30 and 34.9 and 
35+ had a rate ratio of puerperal venous thromboe-
mbolism of 1.7 (95% CI, 1.1 to 2.7), 2.1 (95% CI, 1.1 
to 3.9), and 3.5 (95% CI, 1.8 to 6.7), respectively. 
Women undergoing elective caesarean sections or 
emergency caesarean sections had a rate ratio of 
puerperal venous thromboembolism of 2.1 (95% CI, 
1.4 to 3.1) and 3.0 (95% CI, 2.3 to 4.0), respecti-
vely, compared with women giving birth vaginally. 
Women diagnosed with major postpartum bleeding 
had a rate ratio of puerperal venous thromboembo-
lism of 1.4 (95% CI, 1.0 to 2.1) [6]. We estimated 
the risk of puerperal venous thromboembolism for 
women hospitalized more than 1 day during preg-
nancy according to selected causes of admission to 
hospital [6].
Admission for preeclampsia and a bleeding epi-
sode including abruption placenta and placenta 
previa during pregnancy had a strong thromboge-
nic effect that persisted in the puerperal period. 
The rate ratio for preeclampsia was 5.0 (95% CI, 
3.1 to 7.8) and a bleeding episode 2.1 (95% CI, 1.1 
to 4.3). We found only a modestly elevated increa-
sed risk of puerperal thromboembolism when the 
primary cause of admission during pregnancy was 
threatened preterm labor (1.6 (0.7-4.0)), whereas 
when this diagnosis was combined with one or 
more other diagnoses it was considerably increased 
(3.4 (2.0–6.0)) [6].
Extensive clinical experience and retrospective 
studies have established heparin as the anticoagu-
lant for safe use during pregnancy, do not cross the 
placenta, and therefore does not cause bleeding or 
teratogenic effect on the unborn child [1].
Some authors recommend warfarin use during 
pregnancy in some special circumstances, such as 
in women with mechanical heart valves, those who 
had recurrence while receiving heparin and those 
with contraindications to the use of heparin [1].
The anticoagulants warfarin does not induce 
effects in children fed breast milk and therefore 
can be used safely in the post-period childbirth [1].
Low-molecular-weight heparin (LMWH) is the 
recommended drug for antithrombotic prophylaxis 
and therapy of VTE, and its use in pregnancy has 
greatly increased in recent years. However, mater-
nal mortality has not decreased, as reported by the 
World Health Organization and in a recent worldwi-
de report. The suggested dose varies according to 
LMWH molecules, being 40 mg for sodium enoxa-
parin and 2,850 international unit for calcium na-
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droparin, once a day subcutaneously, that can be 
increased according to maternal increase of body 
weight. The choice of type and dose of LMWH is 
based on physicians’ experiences and varies among 
hospitals and countries [7].
The goal of thromboprophylaxis is to provide VTE 
protection with minimal side effects for the mother 
and no effects on the fetus. Although today we 
have a huge choice of anticoagulant and antiplatelet 
agents, heparin is still the anticoagulant of choice 
for VTE prophylaxis and treatment in pregnancy. 
Currently, LMWHs have replaced UFH as the first 
choice anticoagulant. LMWHs are at least as effecti-
ve as UFH, but produce more predictable anticoagu-
lant response due to better bioavailability (90-100% 
after subcutaneous administration), longer half-life 
(4-6 h), dose-independent renal clearance, decrea-
sed affinity for heparin-binding proteins, endothe-
lial cells and macrophages. Effective anticoagulation 
can be achieved by subcutaneous application of 
LMWH once daily, with no need for routine labo-
ratory monitoring of anti-factor Xa activity in plas-
ma. Nevertheless, in certain situations LMWH dose 
adjustment is necessary and that demands anti-Xa 
level assessment [8].
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